Business Context and Reporting Period
This Form 8-K was filed by NorthView Acquisition Corp. in connection with its proposed business combination with Profusa, Inc. The reported event occurred on March 4, 2024; the filing was signed March 14, 2024. NorthView is expected to be renamed Profusa, Inc., with Profusa becoming a wholly owned subsidiary following closing.
Material Agreement and Transaction Update
On March 4, 2024, NorthView, Profusa and NV Profusa Merger Sub Inc. entered into Amendment No. 3 to their November 7, 2022 Merger Agreement, as previously amended. The amendment revises the definition of Company Reference Value to adjust for financing proceeds and debt conversions that Profusa could receive before the business combination.
The filing does not state the resulting Company Reference Value, the amount of potential financing proceeds, or the amount of debt subject to conversion.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit or loss, cash flow, margins, debt balances, liquidity, or other operating financial metrics.
- The filing does not provide transaction valuation, anticipated enterprise value, sources and uses of funds, or updated capitalization information.
- NorthView securities listed on Nasdaq are common stock under ticker NVAC, rights under NVACR, and redeemable warrants under NVACW.
Outlook, Risks and Contingencies
Completion of the business combination remains subject to stockholder approval and other closing conditions. The transaction could be terminated under specified circumstances, and the filing does not provide a revised closing date.
Identified risks include redemption requests by NorthView public stockholders, transaction costs, failure to realize anticipated benefits, disruption to operations, litigation or regulatory proceedings, and the success and customer acceptance of Profusa’s products and services. The filing also cautions that forward-looking statements regarding timing, financing, market opportunity, operating results and transaction benefits are uncertain.
Investors are directed to the registration statement/proxy statement prospectus on Form S-4 and subsequent SEC filings for additional transaction terms, risk factors and financial information. The filing states that the proxy statement/prospectus should be reviewed before making voting or investment decisions.
Key Facts to Verify
- Review Amendment No. 3 to determine the precise adjustment mechanics for financing proceeds and debt conversions.
- Confirm Profusa’s actual financing proceeds, debt conversions and resulting Company Reference Value.
- Verify stockholder approval, satisfaction of other closing conditions and any updated transaction timetable.
- Assess the level of public-stockholder redemptions and their effect on post-closing liquidity and capitalization.
- Review the definitive proxy statement/prospectus for Profusa’s historical financial statements, projections, risks and detailed transaction terms.